New asthma drug aims to match leading treatment in major trial
NCT ID NCT07302516
First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 16 times
Summary
This study tests if a new drug called QL2302 works as well and is as safe as the current drug Tezspire for adults with severe asthma that is not controlled by standard treatments. About 636 adults aged 18-80 will get either QL2302 or Tezspire as an injection every 4 weeks for 48 weeks. The main goal is to see how many asthma flare-ups each group has.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.